Last update Nov. 22, 2022
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Foscarnet Sodium in other languages or writings:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 12 - 21 | % |
Molecular weight | 300 | daltons |
Protein Binding | 14 - 17 | % |
VD | 0.5 ± 0.2 | l/Kg |
Tmax | 0.01 | hours |
T½ | 3.3 - 6.8 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a non-nucleoside pyrophosphate analog active against herpesviruses. It is used for the treatment of cytomegalovirus retinitis in patients with AIDS and for aciclovir-resistant herpes simplex y varicella-zoster infections in immunocompromised patients. Intravenous administration every 12 hours for 2 to 3 weeks.
At the date of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight and low percentage of plasma protein binding) makes it likely that significant amounts will pass into breast milk.
Its very low oral bioavailability makes it difficult for it to pass to the infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period in which there may be greater intestinal permeability.
Common side effects are kidney failure, which can be severe, and anemia.